Quarterly Activities/Appendix 4C Cash Flow Report

Quarterly Activities/Appendix 4C Cash Flow Report

Radiopharm Theranostics (RAD:AU) has announced Quarterly Activities/Appendix 4C Cash Flow Report

Download the PDF here.

The Conversation (0)
Appendix 4E and Preliminary Final Report

Appendix 4E and Preliminary Final Report

Radiopharm Theranostics (RAD:AU) has announced Appendix 4E and Preliminary Final ReportDownload the PDF here. Keep Reading...
RAD receives IND approval from US FDA for Betabart (RV-01)

RAD receives IND approval from US FDA for Betabart (RV-01)

Radiopharm Theranostics (RAD:AU) has announced RAD receives IND approval from US FDA for Betabart (RV-01)Download the PDF here. Keep Reading...
RAD Granted US FDA Fast Track for RAD101 Metastases Imaging

RAD Granted US FDA Fast Track for RAD101 Metastases Imaging

Radiopharm Theranostics (RAD:AU) has announced RAD Granted US FDA Fast Track for RAD101 Metastases ImagingDownload the PDF here. Keep Reading...
RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202

Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202Download the PDF here. Keep Reading...
RAD Reports Positive Preclinical Lu177-B7H3-mAb Data

RAD Reports Positive Preclinical Lu177-B7H3-mAb Data

Radiopharm Theranostics (RAD:AU) has announced RAD Reports Positive Preclinical Lu177-B7H3-mAb DataDownload the PDF here. Keep Reading...
Double helix DNA with word "ETFs" and biotech stock tickers.

5 Small-cap Biotech ETFs to Watch

Thanks to exchange-traded funds (ETFs), investors don’t have to be tied to one specific stock. When it comes to biotech ETFs, they give sector participants exposure to many biotech companies via one vehicle.ETFs are a popular choice as they allow investors to enter the market more safely... Keep Reading...
Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

Cardiol Therapeutics' ARCHER Phase II Study Results Published in ESC Heart Failure

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced the publication of results from its Phase II ARCHER study... Keep Reading...
Seegnal Inc

Seegnal Expands Deployment of Seegnal's Prescription Intelligence Platform at Tel Aviv Sourasky Medical Center, a Leading Israeli Public Medical Center and Global Referral Center

Seegnal Inc. (TSXV: SEGN), a global leader in clinical decision support solutions applying patient-centric medication safety standards, today announced its deepened partnership with Tel Aviv Sourasky Medical Center ("Sourasky Medical Center"). Israel's second-largest public hospital, Sourasky... Keep Reading...
Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million

Cardiol Therapeutics Announces Closing of Bought Deal Financing and Full Exercise of Over-Allotment Option for Gross Proceeds of $14.85 Million

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has closed its previously announced private... Keep Reading...
Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

Cardiol Therapeutics Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has entered into an agreement with a sole... Keep Reading...
Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

Cardiol Therapeutics Inc. Announces Bought Deal Financing for Gross Proceeds of $13.5 Million

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease, today announced that it has entered into an agreement with Canaccord... Keep Reading...

Interactive Chart

Latest Press Releases

Related News